Upcoming Conferences, Financial Results, Dividends, and Public Offerings - Research Report on Medicines Company, Isis, Ligand, Teleflex, and Tetraphase

12 Nov 2013

NEW YORK, November 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting The Medicines Company (NASDAQ: MDCO), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Teleflex Incorporated (NYSE: TFX), and Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

The Medicines Company Research Report

On November 5, 2013, The Medicines Company (Medicines Company) announced that it will present at the Credit Suisse Healthcare Conference in Arizona on November 12, 2013 at 5:30 p.m. ET (3:30 p.m. MT). Medicines Company informed that the live webcast of the presentation will be available at its website. The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/5a84_MDCO]

Isis Pharmaceuticals, Inc. Research Report

On November 5, 2013, Isis Pharmaceuticals, Inc. (Isis) reported Q3 2013 financial results with revenue of $23.6 million, up 103.3% YoY. For Q3 2013, net loss stood at $24.6 million or $0.21 per basic and diluted share, compared to a net loss of $37.6 million or $0.37 per basic and diluted share in Q3 2012. B. Lynne Parshall, Chief Operating Officer of Isis said, "Our increasingly strong financial performance is a result of meeting key milestones in our partnerships, adding new partners and expanding existing relationships. Our financial success is also driven by achievements from our expanding and maturing pipeline, as well as continuous improvements in our technology platform. We have completed key steps to move two important drugs, ISIS-APOCIIIRx and ISIS-SMNRx, into Phase 3 studies early next year. In addition, our Phase 2/3 study for ISIS-TTRRx is enrolling on schedule, and we are pleased with the progress we and our partner, GlaxoSmithKline, are making to advance this drug towards the market." The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/fcfc_ISIS]

Ligand Pharmaceuticals Incorporated Research Report

On November 7, 2013, Ligand Pharmaceuticals Incorporated (Ligand) announced that it will host an Analyst Day on November 14, 2013 from 9:30 a.m. to 11:30 a.m. CT (7:30 a.m. to 9:30 a.m. PT), at the Drake Hotel in Chicago. The Company informed that in the event, Ligand's Senior Management team will give presentations and will cover various topics including: Company's Shots-on-Goal business model; its transformation and accelerating value creation; new information regarding portfolio assets, partners, and milestones; highlights of Ligand's research and technology; overview of the lead diabetes development program; and the Company's financial outlook for 2014 to 2016. Ligand stated that the presentations will be webcast live at its website and a replay of the same will be available for 90 days. The Full Research Report on Ligand Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/3b8d_LGND]

Teleflex Incorporated Research Report

October 30, 2013, Teleflex Incorporated's (Teleflex) announced that its Board of Directors declared a quarterly cash dividend of $0.34 per share of common stock. The Company informed that the dividend is payable on December 13, 2013, to shareholders of record at the close of business on November 15, 2013. The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9c7d_TFX]

Tetraphase Pharmaceuticals, Inc. Research Report

On November 7, 2013, Tetraphase Pharmaceuticals, Inc. (Tetraphase) announced the pricing of an underwritten public offering of 4.5 million shares of its common stock at a price of $10.00 per share, less underwriting discounts and commissions. The Company informed that the size of the offering was increased from 3.3 million shares to 4.5 million shares, raising total gross proceeds to $45 million. Tetraphase stated that it has also given the underwriters a 30-day option to purchase 675,000 additional shares of common stock on the same terms and conditions. The Company expects the offering to close on or about November 13, 2013. The Full Research Report on Tetraphase Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/02a0_TTPH]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com